How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/moraxella-catarrhalis-chronic-bronchitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Moraxella Catarrhalis Chronic Bronchitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Moraxella Catarrhalis Chronic Bronchitis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Moraxella Catarrhalis Chronic Bronchitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Avelox	Avelox	Novartis Pharmaceuticals		DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Moraxella Catarrhalis Chronic Bronchitis
Bayer AG · 2 drugs in Moraxella Catarrhalis Chronic Bronchitis
Assistance Publique - Hôpitaux de Paris · 1 drug in Moraxella Catarrhalis Chronic Bronchitis
Burke Therap · 1 drug in Moraxella Catarrhalis Chronic Bronchitis
Novartis Pharmaceuticals · 1 drug in Moraxella Catarrhalis Chronic Bronchitis
Poitiers University Hospital · 1 drug in Moraxella Catarrhalis Chronic Bronchitis
Teva Pharmaceuticals USA · 1 drug in Moraxella Catarrhalis Chronic Bronchitis
Vansen Pharma · 1 drug in Moraxella Catarrhalis Chronic Bronchitis
Allergan · 1 drug in Moraxella Catarrhalis Chronic Bronchitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Moraxella Catarrhalis Chronic Bronchitis:

Cite this brief

Drug Landscape (2026). Moraxella Catarrhalis Chronic Bronchitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/moraxella-catarrhalis-chronic-bronchitis. Accessed 2026-06-10.

Moraxella Catarrhalis Chronic Bronchitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing